Psychedelic-assisted therapy and the standard of care

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

For licensed healthcare professionals who want to understand what standard of care applies when they are involved with psychedelic services — as dual-licensed facilitators, referring clinicians, or integration providers — and what the malpractice implications are.

The short answer

No formal clinical standard of care for psilocybin-assisted therapy has been established in the United States as of early 2026. No professional medical or mental health association has published practice guidelines. No FDA-approved indication for psilocybin exists. Oregon’s program was designed as a supported wellness service, not a clinical treatment — and the administrative rules that govern facilitators do not constitute a clinical standard of care in the medical malpractice sense. For a dual-licensed clinician providing services under HB 2387, this creates an unusual situation: they are operating under OPS facilitation rules on one hand and their professional licensing board’s standards of practice on the other, with no settled framework bridging the two. Understanding what courts and boards are likely to look to when evaluating conduct in this space is essential before any clinician engages substantively with psychedelic services.

What “standard of care” means and why it matters

In medical malpractice law, the standard of care is the level of skill, care, and treatment that a reasonably competent healthcare professional in the same or similar specialty would provide under the same or similar circumstances. It is typically established through expert testimony — what would a reasonable physician, therapist, or nurse in this situation have done?

When a patient is harmed and brings a negligence claim, the standard of care is the benchmark against which the clinician’s conduct is measured. Departure from that standard, if it caused the harm, is the basis for liability. The challenge in psychedelic-assisted therapy is that the standard itself is unsettled — there are no published clinical practice guidelines, no board-issued position statements adopting a standard, and no body of appellate case law interpreting what a reasonable clinician does in this context.

What exists in the absence of a formal standard

In the absence of formal guidelines, courts and professional boards will look to several sources when evaluating a clinician’s conduct involving psilocybin services.

The OPS administrative rules (OAR 333-333) establish specific procedural requirements for Oregon’s licensed program. A dual-licensed clinician who violates those rules — fails to obtain required consent, skips required intake procedures, crosses into clinical work during an administration session — has violated a published regulatory standard. Those violations will be evidence in both an OPS proceeding and any civil negligence claim.

Published clinical trial protocols from COMPASS Pathways, Johns Hopkins, NYU, and other research centers have used specific preparation, dosing, psychological support, and integration models. In the absence of formal guidelines, expert witnesses in malpractice cases may draw on these research protocols as evidence of what careful practitioners do.

Emerging training standards from organizations developing psychedelic therapist training — including MAPS Public Benefit Corporation’s MDMA-assisted therapy protocol and various psilocybin training programs — may inform what courts view as reasonable practice, even where those standards are not formally adopted by any licensing board.

A clinician’s own credentials and representations matter significantly. A clinician who holds themselves out as a specialist in psychedelic-assisted therapy, or who markets integration services using language suggesting clinical expertise, will be held to the standard of the specialty they claim. A clinician who discusses psilocybin services as one of many treatment options without claiming specialized expertise occupies a different evidentiary position.

The referring clinician’s exposure

A clinician who refers a patient to Oregon’s licensed psilocybin program, or who discusses psilocybin services as a treatment option under HB 2387, takes on some level of professional responsibility for that discussion. The HB 2387 discussion protection shields the clinician from board discipline for the discussion itself — it does not immunize the clinician from a malpractice claim if the referral was negligent.

A clinician who recommends psilocybin services to a patient without reviewing that patient’s medication list, without flagging relevant contraindications, or without ensuring the patient understands what the services involve may have departed from what a reasonably careful clinician would do. The standard for the discussion is not “say nothing about psilocybin” — it is “discuss it in a way that a reasonable clinician would, given what is known about the patient and the service.”

The medication review obligation is particularly concrete. A prescribing clinician whose patient is on lithium — an absolute exclusion from Oregon’s program — who fails to mention the contraindication before the patient accesses services, faces a fact pattern where the connection between the omission and any harm is direct.

The dual-licensed facilitator’s exposure

A dual-licensed facilitator operating under HB 2387 faces potential liability under two frameworks simultaneously: OPS discipline for violations of OAR 333-333, and professional malpractice for departures from clinical standards during preparation and integration sessions.

The administration session is the clearest boundary: no clinical work during the administration session. A dual-licensed facilitator who provides psychotherapy during an administration session — interpreting the client’s experience, directing the client’s psychological processing, making clinical suggestions during altered states — has violated both OPS rules and, potentially, the standard of care for their clinical profession.

For preparation and integration sessions, the dual-licensed facilitator is operating in territory where both OPS rules and professional clinical standards apply. OPS rules set the floor — the procedural requirements that must be met. Professional clinical standards set an additional layer — the quality and competence of the clinical work within those procedures. A therapist-facilitator who conducts a preparation session meeting all OPS procedural requirements but who misses an obvious clinical contraindication that a reasonable therapist would have caught may have satisfied OPS rules while departing from clinical standards.

The research evidence and what clinicians can say

Two Phase 3 trials of COMPASS Pathways’ synthetic psilocybin (COMP360) met their primary endpoints for treatment-resistant depression — COMP005 in June 2025 and COMP006 in February 2026. A rolling NDA submission to the FDA is projected for late 2026. Evidence also exists for major depressive disorder, end-of-life anxiety and existential distress, alcohol use disorder, and tobacco dependence. For end-of-life distress specifically, the evidence is among the most consistent in the literature.

A clinician who discusses psilocybin’s evidence base with a patient should accurately characterize what the evidence shows — strong signal for certain conditions, limited long-term data, significant methodological challenges around blinding, and the distinction between controlled trial conditions and the Oregon licensed program’s real-world context. Overstating the evidence base creates both ethical and liability exposure, particularly if a patient undergoes services based on clinical representations that exceed what the evidence supports.

Documentation

Because the standard of care in this area is unsettled, documentation is especially important. A clinician who documents their reasoning — why they discussed psilocybin services with this patient, what contraindications they reviewed, what the patient understood about the nature of the services, and what follow-up clinical care was planned — is in a materially better position if a claim arises than one who has no record of that reasoning. Documentation does not substitute for good clinical judgment, but it preserves evidence that good clinical judgment was exercised.

When public information may be enough

COMPASS Pathways publishes its trial data through investor disclosures and peer-reviewed publications. The current evidence base is reviewable through PubMed and systematic reviews published through 2025. OPS’s administrative rules (OAR 333-333) and the informed consent framework are publicly available at oregon.gov/psilocybin. HB 2387’s full text is available through the Oregon Legislative Assembly.

When you should speak with a lawyer

A clinician who has received a patient complaint, a board inquiry, or a malpractice demand related to psilocybin services should retain legal counsel immediately before responding. A dual-licensed facilitator who is uncertain whether their clinical conduct during preparation or integration sessions may have departed from professional standards should consult an attorney before an inquiry materializes. A clinician who wants to establish a practice that involves psilocybin services in any form — referral, integration support, dual-licensed facilitation — should get legal advice about how to structure and document that practice before beginning.

You might also want to read

This article is for general informational purposes only and does not constitute legal or medical advice. The research base and regulatory framework for psychedelic-assisted therapy change rapidly. For clinical guidance specific to your patients or practice, consult current peer-reviewed literature and appropriate medical and legal authorities.